Moreover, it has been commonly agreed that AR expression and signaling remains intact as the disease evolves from androgen-sensitive cancer to castration-resistant prostate cancer (CRPC) which are still dependent on AR signaling axis (Jenster, 1999; Taplin, 2007). The gene discussed is AR; the disease is prostate cancer.